Eli Lilly's Phase 3 Jardiance Study Stopped Early Due To Clear Positive Efficacy In Kidney Disease - Eli

Based on the Independent Data Monitoring Committee's recommendation, Boehringer Ingelheim and Eli Lilly And Co (NYSE:LLY) will stop early its EMPA-KIDNEY trial of Jardiance (empagliflozin) in adults with chronic kidney disease (CKD).
This follows a formal interim assessment that met prespecified criteria for positive efficacy.
As the largest SGLT2 inhibitor trial in CKD to date, the 6,600-subject EMPA-KIDNEY is evaluating the efficacy and safety of Jardiance in adults with CKD who are frequently seen in clinical practice but who have been under-represented in previous SGLT2 inhibitor trials.
Read Next: Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia.
In March 2020, the FDA granted Fast Track designation to the clinical investigation of Jardiance to reduce the risk of kidney disease progression and cardiovascular death in adults with CKD.
Full results from the EMPA-KIDNEY trial will be presented at an upcoming medical congress.
Price Action: LLY shares are up 0.20% at $276 during the market session on the last check Wednesday.

To add Benzinga News as your preferred source on Google, click here.